About Kodiak Sciences
Kodiak Sciences is a company based in Palo Alto (United States) founded in 2009. Kodiak Sciences has raised $35.84 million across 3 funding rounds from investors including Perceptive Advisors and ArrowMark Partners. The company has 109 employees as of December 31, 2024. Kodiak Sciences offers products and services including Tarcocimab Tedromer, KSI-501, and KSI-101. Kodiak Sciences operates in a competitive market with competitors including argenx, MacroGenics, Alexion, Zai Lab and Visterra, among others.
- Headquarter Palo Alto, United States
- Employees 109 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kodiak Sciences Inc
-
Annual Revenue
Not available
-
Net Profit
-$176.21 M (USD)32.36as on Dec 31, 2024
-
EBITDA
-$160.14 M (USD)36.29as on Dec 31, 2024
-
Total Equity Funding
$35.84 M (USD)
in 3 rounds
-
Latest Funding Round
$33 M (USD), Debt – Conventional
Apr 26, 2018
-
Investors
Perceptive Advisors
& 1 more
-
Employee Count
109
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Kodiak Sciences
Kodiak Sciences is a publicly listed company on the NASDAQ with ticker symbol KOD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Kodiak Sciences
Kodiak Sciences offers a comprehensive portfolio of products and services, including Tarcocimab Tedromer, KSI-501, and KSI-101.
Provides durable treatment for retinal vascular diseases through biopolymer conjugates.
Targets inflammation and permeability in high-prevalence retinal conditions.
Treats macular edema linked to inflammation in retinal disorders.
People of Kodiak Sciences
Unlock access to complete
Unlock access to complete
Funding Insights of Kodiak Sciences
Kodiak Sciences has successfully raised a total of $35.84M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $33 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kodiak Sciences
Kodiak Sciences has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Perceptive Advisors and ArrowMark Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Diversified asset management services are provided to investors.
|
Locked | Locked | Locked |
Investor details for Kodiak Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kodiak Sciences
Investment portfolio details for Kodiak Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kodiak Sciences
Detailed financials for Kodiak Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kodiak Sciences Comparisons
Peer comparison for Kodiak Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kodiak Sciences
Kodiak Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as argenx, MacroGenics, Alexion, Zai Lab and Visterra, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company focused on cancer therapeutics development.
|
|
| Locked | Locked | Locked |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| Locked | Locked | Locked |
Antibody-based therapies for cancers and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of monoclonal antibodies against infectious diseases
|
Detailed competitors of Kodiak Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kodiak Sciences
Complete news archive for Kodiak Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kodiak Sciences
Kodiak Sciences was founded in 2009.
Kodiak Sciences is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Kodiak Sciences is a funded company, having raised a total of $35.84M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Kodiak Sciences is 109.
The company was founded in 2009 in Palo Alto, United States, and operates in the biotechnology sector. Focus is placed on developing therapeutics for retinal diseases, with two candidates in clinical stages: KSI-301 targeted at age-related macular degeneration and KSI-501 for dry age-related macular degeneration. These products are based on proprietary antibody bioconjugate platforms, supporting treatment advancements in ophthalmology.
Kodiak Sciences's top competitors include argenx, Zai Lab and MacroGenics.
Kodiak Sciences offers Tarcocimab Tedromer, KSI-501, and KSI-101.
Yes, Kodiak Sciences is publicly traded on NASDAQ under the ticker symbol KOD.
Kodiak Sciences has 2 investors. Key investors include Perceptive Advisors, and ArrowMark Partners.
The ticker symbol of Kodiak Sciences is KOD on NASDAQ.